Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hidekazu Shirota

Showing results (51-60 of 90) with videos related to

Pageof 9
Sort By:
International Journal of Colorectal Disease|June 11, 2024
Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trialKota Ouchi, Shin Takahashi, Keiju Sasaki, et al.
Cancer Management and Research|November 6, 2019
Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective studyHiroo Imai, Ken Saijo, Keigo Komine, et al.
Plos One|May 11, 2017
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysisMasanobu Takahashi, Keigo Komine, Hiroo Imai, et al.
Scientific Reports|November 15, 2024
Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumabYuki Kasahara, Ken Saijo, Reio Ueta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2026
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapyShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
Anticancer Research|November 29, 2023
FOLFIRI Chemotherapy for Patients With Metastatic Urachal CarcinomaSakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, et al.
Discover Oncology|April 7, 2025
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phaseKen Saijo, Hiroo Imai, Yuki Kasahara, et al.
International Journal of Clinical Oncology|February 28, 2025
Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test databaseSakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, et al.
Oncology|September 14, 2023
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell CarcinomaReio Ueta, Hiroo Imai, Ken Saijo, et al.
International Journal of Molecular Sciences|August 14, 2025
Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell CarcinomaTomoyuki Iwasaki, Hidekazu Shirota, Eiji Hishinuma, et al.
Pageof 9

Showing results (51-60 of 90) with videos related to

Sort By:
Pageof 9
International Journal of Colorectal Disease|June 11, 2024
Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trialKota Ouchi, Shin Takahashi, Keiju Sasaki, et al.
Cancer Management and Research|November 6, 2019
Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective studyHiroo Imai, Ken Saijo, Keigo Komine, et al.
Plos One|May 11, 2017
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysisMasanobu Takahashi, Keigo Komine, Hiroo Imai, et al.
Scientific Reports|November 15, 2024
Pretreatment neutrophil-lymphocyte ratio as a prognostic factor in recurrent/metastatic head and neck cancer treated with pembrolizumabYuki Kasahara, Ken Saijo, Reio Ueta, et al.
European Journal of Cancer (Oxford, England : 1990)|May 26, 2026
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapyShiori Ishikawa, Kota Ouchi, Shonosuke Wakayama, et al.
Anticancer Research|November 29, 2023
FOLFIRI Chemotherapy for Patients With Metastatic Urachal CarcinomaSakura Hiraide Taniguchi, Keigo Komine, Noriko Takenaga, et al.
Discover Oncology|April 7, 2025
A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phaseKen Saijo, Hiroo Imai, Yuki Kasahara, et al.
International Journal of Clinical Oncology|February 28, 2025
Impact of genetic mutations on prognosis and chemotherapy efficacy in advanced appendiceal carcinoma: insights from the nationwide Japanese comprehensive genomic profiling test databaseSakura Hiraide Taniguchi, Masanobu Takahashi, Shih-Wei Chiu, et al.
Oncology|September 14, 2023
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell CarcinomaReio Ueta, Hiroo Imai, Ken Saijo, et al.
International Journal of Molecular Sciences|August 14, 2025
Plasma Lysophosphatidylcholine Levels Correlate with Prognosis and Immunotherapy Response in Squamous Cell CarcinomaTomoyuki Iwasaki, Hidekazu Shirota, Eiji Hishinuma, et al.
Pageof 9